Home/cascade-timeline/FDA Prescription Drug User Fee Act Creates Financial Dependence on Pharmaceutical Industry

FDA Prescription Drug User Fee Act Creates Financial Dependence on Pharmaceutical Industrytimeline_event

regulatory-capturepharmaceutical-industryfdagovernment-fundinginstitutional-transformation
1992-10-29 · 1 min read · Edit on Pyrite

type: timeline_event

The Prescription Drug User Fee Act (PDUFA) of 1992 fundamentally restructured FDA drug approval financing by creating a direct financial relationship between pharmaceutical companies and regulators. The Act mandated drug companies pay fees to fund FDA drug reviews, which eventually comprised up to 65% of the FDA's drug review budget. By 2025, these user fees reached $3.3 billion of the FDA's $6.9 billion total budget, raising significant concerns about regulatory independence.

Key Impacts:

  • Reduced drug approval times from 31 months to 14.5 months
  • Created mandatory five-year reauthorization negotiations
  • Established a structural mechanism for pharmaceutical industry influence
  • Shifted FDA financial dependence toward industry funding

    • The legislation represents a critical moment in regulatory capture, where the oversight mechanism became financially dependent on the entities it regulates.